Chapter/Section Purchase

1 Study Coverage
1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 PRM-167
1.2.3 XOMA-089
1.2.4 Others
1.3 Market by Application
1.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 ASCs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Estimates and Forecasts 2017-2028
2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Estimates and Forecasts 2017-2028
2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region
2.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2017-2022)
2.4.2 Global Sales Proliferative Vitreoretinopathy (PVR) Therapeutics by Region (2023-2028)
2.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
2.5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2017-2022)
2.5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers
3.1.1 Global Top Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers by Sales (2017-2022)
3.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics in 2021
3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers
3.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2017-2022)
3.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue in 2021
3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type
4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historical Sales by Type (2017-2022)
4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Sales by Type (2023-2028)
4.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2017-2028)
4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type
4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historical Revenue by Type (2017-2022)
4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Revenue by Type (2023-2028)
4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2017-2028)
4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type
4.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2017-2022)
4.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application
5.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historical Sales by Application (2017-2022)
5.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Sales by Application (2023-2028)
5.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2017-2028)
5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application
5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historical Revenue by Application (2017-2022)
5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Revenue by Application (2023-2028)
5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2017-2028)
5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application
5.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2017-2022)
5.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price Forecast by Application (2023-2028)
6 North America
6.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
6.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2017-2028)
6.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2017-2028)
6.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
6.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2017-2028)
6.2.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2017-2028)
6.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
6.3.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2017-2028)
6.3.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
7.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2017-2028)
7.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2017-2028)
7.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
7.2.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2017-2028)
7.2.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2017-2028)
7.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
7.3.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2017-2028)
7.3.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
8.1.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2017-2028)
8.1.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2017-2028)
8.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
8.2.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2017-2028)
8.2.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2017-2028)
8.3 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region
8.3.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2017-2028)
8.3.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
9.1.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2017-2028)
9.1.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2017-2028)
9.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
9.2.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2017-2028)
9.2.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2017-2028)
9.3 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
9.3.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2017-2028)
9.3.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
10.1.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2017-2028)
10.1.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2017-2028)
10.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
10.2.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2017-2028)
10.2.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2017-2028)
10.3 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
10.3.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2017-2028)
10.3.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Overview
11.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis AG Recent Developments
11.2 Promedior Inc
11.2.1 Promedior Inc Corporation Information
11.2.2 Promedior Inc Overview
11.2.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Promedior Inc Recent Developments
11.3 RXi Pharmaceuticals Corp
11.3.1 RXi Pharmaceuticals Corp Corporation Information
11.3.2 RXi Pharmaceuticals Corp Overview
11.3.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 RXi Pharmaceuticals Corp Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Chain Analysis
12.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process
12.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales and Marketing
12.4.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels
12.4.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
12.5 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
13.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Drivers
13.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Challenges
13.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Restraints
14 Key Findings in The Global Proliferative Vitreoretinopathy (PVR) Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer